Paradigm Biopharmaceuticals Ltd (PAR) - Cash Flow Conversion Efficiency

Latest as of December 2025: -3.276x

Based on the latest financial reports, Paradigm Biopharmaceuticals Ltd (PAR) has a cash flow conversion efficiency ratio of -3.276x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-19.65 Million ≈ $-13.90 Million USD) by net assets (AU$6.00 Million ≈ $4.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Paradigm Biopharmaceuticals Ltd (PAR) market capitalisation for the company's overall valuation and market capitalisation.

Paradigm Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Paradigm Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Paradigm Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Paradigm Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency. See Paradigm Biopharmaceuticals Ltd cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Ampire Co Ltd TWO:8049	0.048x
Aifeex Nexus Acquisition Corporation NASDAQ:AIFE	-0.002x
NFC Corporation KQ:265740	0.036x
Se Gyung Hi Tech Co.Ltd KQ:148150	0.004x
The Platform Group AG XETRA:TPG	0.113x
Bon Fame Co Ltd TWO:8433	0.008x
E-Data Teknoloji Pazarlama AS IS:EDATA	-0.251x
KHD Humboldt Wedag International AG XETRA:KWG	0.191x

Annual Cash Flow Conversion Efficiency for Paradigm Biopharmaceuticals Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Paradigm Biopharmaceuticals Ltd from 2014 to 2025. View Paradigm Biopharmaceuticals Ltd (PAR) stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$21.18 Million ≈ $14.99 Million	AU$-15.99 Million ≈ $-11.32 Million	-0.755x	+72.75%
2024-06-30	AU$23.81 Million ≈ $16.84 Million	AU$-65.94 Million ≈ $-46.66 Million	-2.770x	-229.06%
2023-06-30	AU$53.68 Million ≈ $37.98 Million	AU$-45.19 Million ≈ $-31.97 Million	-0.842x	-10.60%
2022-06-30	AU$42.31 Million ≈ $29.94 Million	AU$-32.21 Million ≈ $-22.79 Million	-0.761x	-70.56%
2021-06-30	AU$78.27 Million ≈ $55.38 Million	AU$-34.93 Million ≈ $-24.71 Million	-0.446x	-378.45%
2020-06-30	AU$108.18 Million ≈ $76.55 Million	AU$-10.09 Million ≈ $-7.14 Million	-0.093x	-21.34%
2019-06-30	AU$82.81 Million ≈ $58.59 Million	AU$-6.37 Million ≈ $-4.50 Million	-0.077x	+82.28%
2018-06-30	AU$13.86 Million ≈ $9.81 Million	AU$-6.01 Million ≈ $-4.25 Million	-0.434x	-29.92%
2017-06-30	AU$13.39 Million ≈ $9.47 Million	AU$-4.47 Million ≈ $-3.16 Million	-0.334x	-4.51%
2016-06-30	AU$11.23 Million ≈ $7.95 Million	AU$-3.59 Million ≈ $-2.54 Million	-0.319x	-284.01%
2015-06-30	AU$14.46 Million ≈ $10.23 Million	AU$-1.20 Million ≈ $-851.40K	-0.083x	-102.05%
2014-06-30	AU$-151.87K ≈ $-107.45K	AU$-617.72K ≈ $-437.08K	4.068x	--

About Paradigm Biopharmaceuticals Ltd

AU:PAR Australia Biotechnology

Market Cap

$91.09 Million

AU$128.74 Million AUD

Market Cap Rank

#19628 Global

#642 in Australia

Share Price

AU$0.25

Change (1 day)

+0.00%

52-Week Range

AU$0.14 - AU$0.45

All Time High

AU$4.35